What are the age restrictions and dosing recommendations for triptans in patients under 18 years old?

Triptan Age Restrictions and Dosing in Pediatric Patients

Triptans are approved for adolescents aged 12-17 years, with ibuprofen remaining first-line treatment for all pediatric migraine patients, and nasal spray formulations of sumatriptan and zolmitriptan showing the most effectiveness when triptans are needed. 1

Age-Based Treatment Algorithm

Children Under 12 Years

• Do not use triptans - clinical trials have failed to demonstrate benefit over placebo in this age group due to high placebo response rates 1
• First-line: Ibuprofen at weight-appropriate dosing 1
• Adjunct: Bed rest alone may suffice for short-duration attacks 1
• For nausea: Domperidone is contraindicated under age 12 1

Adolescents 12-17 Years

Treatment Hierarchy:

1. First-line: Ibuprofen or other NSAIDs 1, 2

2. Second-line (when NSAIDs fail after 3 consecutive attacks):

   • Nasal spray triptans (most effective formulations):

     • Sumatriptan nasal spray 1
     • Zolmitriptan nasal spray 1

   • Oral triptans (FDA-approved options):

     • Rizatriptan ODT 2
     • Almotriptan oral 2, 3
     • Sumatriptan/naproxen combination 2

3. If first triptan fails: Switch to a different triptan - approximately 10% of patients who discontinue try another triptan, but this switching strategy can improve outcomes 1, 2

Critical Clinical Considerations

Contraindications in Adolescents

Avoid triptans in patients with:

• Hemiplegic migraine 4
• Basilar migraine 4, 5
• Known cardiovascular risk factors 4
• Prior cardiac or cerebral ischemia 4
• Uncontrolled hypertension 5
• Renal or hepatic disease 4
• Pregnancy or lactation 4

Timing and Formulation Selection

Choose nasal spray formulations when:

• Headache pain spikes quickly 2
• Significant nausea/vomiting present 1, 2
• Oral administration unlikely to prevent vomiting 1

Counsel patients to treat early in the attack for optimal efficacy 2

The Placebo Problem

The evidence base for triptans in pediatrics is significantly confounded by placebo response rates ranging from 25-57% in clinical trials 1, 6. This high placebo response explains why demonstrating triptan benefit in children has been challenging, despite their proven efficacy in adults. Clinicians should discuss with families that placebo was as effective as medication in many trials before initiating preventive therapy 2.

Important Nuances

• Trial duration matters: Give each triptan a fair trial over 2-3 headache episodes before abandoning that medication 7
• Rizatriptan success: The FDA approval of rizatriptan (ages 6-17) was based on a novel study design enrolling only patients with unsatisfactory response to NSAIDs/acetaminophen and migraine lasting >3 hours 8
• Combination therapy: Triptan-NSAID combinations show efficacy and may be considered 8

When to Refer

Refer to specialist care when:

• Acute medication provides insufficient pain relief after optimizing treatment through the stepped approach 1
• Multiple triptans have failed 1
• Contraindications exist but severe migraine requires specialized management 1

Common Pitfalls to Avoid

1. Don't prescribe triptans under age 12 - no proven benefit and not approved 1
2. Don't skip NSAIDs - they should be tried first in all age groups 1, 2
3. Don't give up after one triptan fails - individual responses vary significantly 1, 2
4. Don't overlook cardiovascular screening - even in adolescents, assess for risk factors before prescribing 4, 5
5. Don't forget antiemetics - add when needed rather than abandoning triptan therapy 2